H.C. Wainwright analyst Yi Chen raised the firm’s price target on LifeMD (LFMD) to $14 from $12 and keeps a Buy rating on the shares. The ...
Full Year 2024 Results Key Financial Results Revenue: US$212.5m (up 39% from FY 2023). Net ...
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Xtant Medical Holdings (XTNT – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback